reports
- Maxim Jacobs
Clal Biotechnology Industries - MediWound updates development plans
Clal Biotechnology Industries (CBI) recently published its Q219 update. Notably, MediWound (35% owned by CBI) announced that following a meeting to discuss the submission of a biologics licensing application (BLA) with the FDA, it expects to file for approval for NexoBrid in Q220. The submission needs to wait for the 12-month follow-up results from the Phase III DETECT study (acute data were released in January). MediWound expects to initiate a 174-patient Phase II study of EscharEx to treat ven...
- Maxim Jacobs
Clal Biotechnology Industries - A licensing deal for MediWound
Clal Biotechnology Industries (CBI) recently published its first quarter update. Notably, MediWound has licensed North American commercialisation rights for NexoBrid to Vericel for $17.5m upfront, with an additional $132.5m in potential milestones. Also, Gamida Cell is on track to complete enrolment for its Phase III trial of NiCord (now called omidubicel) in haematological malignancies in H219 with data expected in H120. In addition, Cadent received a $15m milestone payment from Novartis as MIJ...
- Maxim Jacobs
Clal Biotechnology Industries - Full-year financial results
Clal Biotechnology Industries’ (CBI’s) portfolio of investments continues to advance on multiple fronts. MediWound recently reported positive top-line data from its US Phase III study of NexoBrid, and if all goes according to plan, the company expects to file a BLA application with the FDA in H219. Additionally, according to Gamida Cell, its cash balance should provide a runway through March 2020, which is roughly in line with company expectations for delivering top-line NiCord Phase III dat...
- Maxim Jacobs
Clal Biotechnology Industries - Gamida Cell lists on NASDAQ
Q318 was an active period for Clal Biotechnology Industries’ (CBI’s) portfolio of investments on multiple fronts. First and most notably, Gamida Cell completed a ~$53m IPO on the NASDAQ under the symbol GMDA and plans to present NiCord immune reconstruction (IR) data at the American society of Haematology (ASH) meeting on 1 December. We expect Anchiano to list in the US in the coming months pending market conditions. MediWound slightly delayed its NexoBrid Phase III data readout by one quart...
- Maxim Jacobs
Clal Biotechnology Industries - Progress on multiple fronts
Clal Biotechnology Industries’ (CBI’s) portfolio of investments continues to make headway. MediWound is in advanced discussions with multiple third parties interested for a strategic transaction. With $23m in proceeds from its recent financing, Anchiano Therapeutics (previously BioCanCell) plans to initiate the first of two trials for its lead development programme in H218. Lastly, Gamida Cell recently reported preliminary safety and efficacy data from its donor-derived natural killer (NK) c...
- Maxim Jacobs
Clal Biotechnology Industries - Portfolio progress continues
Clal Biotechnology Industries’ (CBI) portfolio of investments continues to demonstrate forward-looking business development and clinical progress. Notably, MediWound announced in May that it is now in discussions with multiple third parties interested in a strategic transaction. Still, the nature of these approaches remains unclear. Also, BioCanCell announced a $23m private equity investment and plans to use the proceeds to initiate two studies for its lead programme. Lastly, Neon filed a pros...
- Maxim Jacobs
Clal Biotechnology Industries - A strategic approach to MediWound
Clal Biotechnology Industries’ (CBI’s) portfolio of investments continues to progress on multiple fronts. Most importantly, MediWound (CBI owns a 35% stake) announced in March that it had been approached by a third party to consummate a strategic transaction. The exact nature of the proposed transaction is unclear and could range from a product out-licensing to the acquisition of all of MediWound. The companies are in advanced discussions and conducting mutual due diligence.
- Maxim Jacobs
Clal Biotechnology Industries - Israeli science, worldwide presence
We are initiating coverage on Clal Biotechnology Industries (CBI), an Israel/Boston-based healthcare investment company with an extensive portfolio incorporating a diverse range of technologies, indications and stages of development. CBI holds direct investments in 10 companies (nine biotech and one medical device company), most importantly MediWound, a NASDAQ-listed wound care company, and Gamida Cell, which is developing a universal bone marrow transplant (BMT) product. Also, BioCanCell and Bi...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.